• CPHI Milan 2026: Molecule First, Patient Always - Chris Davison
    Nov 16 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoCentrix Pharma Solutions helps biotech companies move from preclinical development into early stage clinical development. For CEO Chris Davison, that means the molecule first and the patient always: "we don't just make a product, we make medicines."This week on Making It In Manufacturing, Harry Sloan sat down with Chris Davison, CEO of Centrix Pharma Solutions, a small CDMO based in the UK, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Chris covers:(00:57) What Centrix does: formulation, analytical work and clinical manufacturing for biotech companies heading into the clinic, and what "Molecule First, Patient Always" means in practice.(02:23) His path to CEO: a pharmacist by training, 23 years at GSK in pharmaceutical development and leading CMC teams, then manufacturing supply chain and launches, before moving to Custom Pharmaceuticals and stepping up to lead the business.(04:03) Going from big pharma to a small company: wearing multiple hats, relying on your network, and not being afraid to ask for help.(05:16) Why now was the time to launch Centrix out of Custom Pharmaceuticals, a business that has been around for 47 years, and why it helps clients with what they need today and what they will need tomorrow.(07:23) Partnership, not transactions: challenging small biotechs on the consequences of their decisions down the line, so they make them with their eyes wide open.(09:41) The Integrated CMC Partnership with Sai Life Sciences and Agility Life Sciences, built to take the handoff out between drug substance and drug product.(12:28) Backing the growth plans: equipment that gives very rich data from small amounts of material, and an Innovate UK knowledge transfer partnership with the University of Sussex that brings a data scientist into the business.(15:05) What growth depends on: clients, the funding bar for biotech, and talent, with recent recruits from Brighton University, and why the people in a business drive its credibility.(18:12) How biotechs now choose a development partner: shorter runways, more selective, and wanting help to navigate their own journey rather than just a formulation and a batch.(19:09) Where AI fits at Centrix today: models to inform drug development, help in the quality functions with the human still at the centre, and empowering the workforce rather than replacing it.(21:40) What he wants Centrix to have delivered a year from now.Watch the full episode to hear why Chris wants more people to know what it really takes to develop a product.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentChris DavisonLinkedIn: https://www.linkedin.com/in/chrisdavison155/Harry SloanLinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/Timestamps:00:00 Introduction00:57 What Centrix does02:23 From pharmacist to CEO04:03 Big pharma to a small company05:16 Why launch Centrix now07:23 Partnership, not transactions09:41 The Integrated CMC Partnership12:28 Investing in data and growth15:05 What growth depends on18:12 How biotechs choose a partner19:09 Where AI fits today21:40 A year from now#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biotech #CMC #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    23 mins
  • CPHI Milan 2026: Capacity Is Not The Issue Anymore, It's Certainty - Katie Edgar and Sigma Mostafa
    Nov 13 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFive years ago, everybody was focused on capacity. For Katie Edgar and Sigma Mostafa of KBI Biopharma, capacity is not the issue anymore: what customers need is certainty, and it starts with planning for the problems before they happen.This week on Making It In Manufacturing, Elliot Payne sat down with Katie Edgar, Chief Business Officer, and Sigma Mostafa, Chief Scientific & Technology Officer at KBI Biopharma, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Katie and Sigma cover:(00:29) What KBI Biopharma does: an end-to-end CDMO in mammalian and microbial, from pre-clinical to commercial manufacturing, with four commercial products and 50 plus early stage molecules a year.(01:22) Katie's journey from strategy and law to leading business development as Chief Business Officer.(03:45) Why Katie calls herself a paid pessimist, and how setting expectations early gives customers certainty.(05:32) How the two work together, and their advice for anyone stepping into a C-suite role, especially women.(07:16) Sigma's journey at KBI, from building process development from the ground up to leading about 500 people.(09:09) Failing fast, learning fast, and taking accountability as a leader.(12:21) Whether it's getting better for women in the industry, and why a strategy to come back after time off matters.(13:25) What makes KBI a technical powerhouse but nimble, in its 30th anniversary year.(17:28) Scientific depth with commercial sense, and why the quality of the data is the differentiator.(21:10) Celebrating the wins, and KBI's monthly win room.(23:48) The one thing they would remove from pharma manufacturing.Watch the full episode to hear why Katie believes the market now wants certainty, not capacity.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentKatie EdgarLinkedIn: [Katie Edgar LinkedIn]Sigma MostafaLinkedIn: [Sigma Mostafa LinkedIn]Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:29 What KBI Biopharma does01:22 Katie's journey03:45 The paid pessimist05:32 Stepping into the C-suite07:16 Growing with KBI09:09 Failing fast and accountability12:21 Women in the industry13:25 Technical powerhouse, but nimble17:28 Science, business and data21:10 Celebrating the wins23:48 One thing to remove from the industry#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biologics #WomenInLeadership #Leadership Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    28 mins
  • CPHI Milan 2026: Can The Asset Deliver The Value? - Sven Remmerbach
    Nov 13 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoWhen a private equity firm looks at a pharma manufacturing site, the financial analysis can tell it what happened. Sven Remmerbach, Managing Director of pharmBridge, answers the simpler question: can the asset deliver the value the investor is looking for?This week on Making It In Manufacturing, Elliot Payne sat down with Sven Remmerbach, Managing Director of pharmBridge, who ran two manufacturing sites at Baxter before moving into consulting, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Sven covers:(00:58) His path from pharmacy studies and a PhD, through internships in hospital and local pharmacies and in industry, into pharmaceutical manufacturing.(02:16) What pharmBridge offers: senior leaders and project experts who help pharma companies execute transformations, technology transfers and strategic investments.(02:45) Why he stayed at Baxter so long: learning in its contract manufacturing business, P&L responsibility, and a mission of serving patients.(04:13) His most rewarding period: the early days of contract manufacturing, on the front line with clients.(05:33) Advice for anyone stepping up to run large teams across sites: shared values, shared goals, smart KPIs and daily disciplines.(06:45) Whether leadership came naturally, and how he learned it from small teams upwards.(07:53) Moving from running sites to consulting, where nobody books your flights any more.(09:00) What pharmBridge does when a PE firm brings it in to look at a pharma manufacturing asset.(10:01) The one question PE firms should ask themselves before acquiring a site.(11:31) Whether he's enjoying it: faster decision cycles, and the freedom to just do things.(12:00) The one thing he would take out of pharma manufacturing.Watch the full episode to hear why Sven believes the organisation can matter more than the equipment.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentSven RemmerbachLinkedIn: [Sven Remmerbach LinkedIn]Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:58 From pharmacy to manufacturing02:16 What pharmBridge offers02:45 Why he stayed at Baxter04:13 His most rewarding role05:33 Leading large teams across sites06:45 Learning to lead07:53 From site leader to consultant09:00 Working with PE firms10:01 One question for PE buyers11:31 Enjoying the freedom12:00 One thing to remove from the industry#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PrivateEquity #Leadership #PharmaManufacturing #TechTransfer Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    14 mins
  • CPHI Milan 2026: Getting Trial Medicines From A To B - Catherine Parry and Jamie Beaumont
    Nov 10 2026

    COREX has spent 15 years moving clinical trial supplies and medicines across the globe. It doesn't manufacture anything. Its job is to make sure what sponsors make gets from A to B, and that the medicines they need are sourced, relabelled and delivered from B to C.


    This week on Making It In Manufacturing, Ruby Collier sat down with Jamie Beaumont, Global Head of Clinical Trial Sourcing, and Catherine Parry, Business Development Director at COREX, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Jamie and Catherine cover:


    (01:05) What COREX does: clinical trial logistics, named patient programmes, and sourcing the commercial medicines sponsors and CROs need for their studies.


    (02:21) Where COREX sits in the supply chain, alongside CROs, CDMOs, biotechs and sponsors.


    (03:01) Why they both joined COREX this year: its reputation for customer service, and the push into international and emerging markets.


    (05:08) What happens when a sponsor needs a comparator, from central sourcing in bulk to buying in a single country for a single patient.


    (06:26) When sponsors realise they have a supply problem (probably too late), and why the conversation should start earlier.


    (07:49) What's driving COREX's growth after 15 years: more services, in more countries.


    (08:58) How COREX competes with the giant logistics players: reliability, supply chain security, knowledge and the personal touch.


    (10:33) The next three to five years: busier trials, more flexible supply, less wastage, and more focus on recruiting and keeping patients.


    (13:32) One piece of advice for a sponsor starting a global trial tomorrow.


    Listen to the full episode to hear why, for COREX, there's always a patient at the end of the service.


    Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Catherine Parry

    LinkedIn: https://www.linkedin.com/in/catherine-parry-55107a4b/


    Jamie Beaumont

    LinkedIn: https://www.linkedin.com/in/jamie-beaumont-2b63b9250/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/rubycollier/


    Timestamps:


    00:00 Introduction

    01:05 What COREX does

    02:21 Where COREX sits in the supply chain

    03:01 Why they joined COREX

    05:08 Inside comparator sourcing

    06:26 Why sponsors call too late

    07:49 What's driving the growth

    08:58 Competing with the giants

    10:33 The next three to five years

    13:32 One piece of advice


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ClinicalTrials #ClinicalSupply #ComparatorSourcing #PharmaLogistics

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    15 mins
  • CPHI Milan 2026: The Biosimilar Boom Has Flipped Supply And Demand - Himanshu Gadgil
    Nov 6 2026

    This week on Making It In Manufacturing, Elliot Payne sat down again with Himanshu Gadgil, Ph.D., CEO of Enzene, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Himanshu covers:


    (00:54) Enzene's last 12 months: the Manufacturing Excellence Award, its New Jersey facility fully running with two suites, and a full technology transfer offer for anyone who wants to onshore manufacturing.


    (02:12) Why Enzene is opening up its continuous manufacturing platform: to reach the tipping point where a lot more people adopt it.


    (02:59) The biosimilar boom seen at CPHI this year, and why the supply and demand equation has flipped.


    (04:30) How Enzene stands out: a platform built for India's price-sensitive market, so it was cost effective from the start.


    (05:58) What comes next for EnzeneX®: from 200 litres to 1,000 litres in 2.0, then process analytics, its own media, and AI that makes process decisions dynamically.


    (07:23) Intuition or data: how he makes decisions, and how AI gives the team very quick access to what the data is saying.


    (08:59) The decisions that shaped Enzene: becoming a full CDMO, and moving into pet health, where it works with four of the top five pet health companies.


    (10:13) The one process he would remove from pharma manufacturing.


    Watch the full episode to hear why Himanshu believes the best cost of goods will win as so many biologics come off patent.


    Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/


    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw


    Instagram: https://www.instagram.com/arto.talent


    TikTok: https://www.tiktok.com/@artotalent


    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245


    Website: https://arto-talent.com/


    Youtube: https://www.youtube.com/@artotalent


    Himanshu Gadgil


    LinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/


    Elliot Payne


    LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/


    Timestamps:


    00:00 Introduction


    00:54 Enzene's last 12 months


    02:12 Opening up continuous manufacturing


    02:59 The biosimilar boom


    04:30 Winning on cost of goods


    05:58 EnzeneX® 3.0 and beyond


    07:23 Intuition, data and AI


    08:59 Decisions that shaped Enzene


    10:13 One thing to remove from the industry


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Biosimilars #ContinuousManufacturing #Biologics #CDMO

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    11 mins
  • CPHI Milan 2026: The White Drums With The Red Lid - Bart van Berkel
    Nov 5 2026

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Many in the pharma industry know CurTec for its white drums with the red lid, used to handle, store and contain the ingredients that go into medicines. CEO Bart van Berkel explains why pharma is the only industry CurTec focuses on.


    This week on Making It In Manufacturing, Harry Sloan sat down with Bart van Berkel, CEO of CurTec, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Bart covers:


    (01:00) What CurTec does: packaging that helps pharmaceutical companies, API and excipient suppliers and CMOs handle, store and contain the ingredients used to make medicines.


    (01:32) What carried over from aerospace: a highly regulated industry, long customer relationships, high standards of quality, and approval processes that take long for a good reason.


    (02:59) What makes a drum or pail pharmaceutical grade: easy to operate in suits and gloves, screw lids, GMP at the core, and designs that can dock to isolators.


    (04:16) Sustainability: taking material out, packaging that can be reused, and a redesigned drum with no handles or rubber gasket and a 30% CO2 reduction against CurTec's own products.


    (05:27) Why CurTec, opened in the 1950s in the Netherlands, built a factory in South Carolina and moved all its American customers to it.


    (07:35) Building greenfield to embed the CurTec culture of safety, compliance and cleanliness from the start, with a team of 30 and growing.


    (08:52) How pharma supply chains are shifting, and CurTec's commercial team in Asia working with suppliers of APIs and excipients.


    (10:01) Where CurTec could be in five years: very likely a facility in Asia, and new products that take it closer to pharma operations.


    (10:49) What he wants people to remember: CurTec is super dedicated to the pharma industry.


    Watch the full episode to hear why Bart wants anyone with a packaging problem to give CurTec a call.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Bart van Berkel

    LinkedIn: https://www.linkedin.com/in/bart-van-berkel-3824b3/


    Harry Sloan

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/


    Timestamps:

    00:00 Introduction

    01:00 What CurTec does

    01:32 From aerospace to pharma

    02:59 What makes packaging pharma grade

    04:16 Sustainability and lighter drums

    05:27 Why South Carolina

    07:35 Building the CurTec culture

    08:52 How pharma supply chains are changing

    10:01 CurTec in five years

    10:49 What to remember about CurTec


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PharmaPackaging #Sustainability #GMP #PharmaSupplyChain

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    12 mins
  • CPHI Milan 2026 Newsbeat: The Digital CMC Consortium Launches To Digitise CMC - Luke Guerrero
    Nov 4 2026

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    On the first day of CPHI Milan 2026, the Digital CMC Consortium launched: a pre-competitive, not-for-profit collaboration across the industry to digitise end-to-end CMC, founded with participation from companies including Novartis, Takeda and Thermo Fisher.


    On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Luke Guerrero, one of the founding members and now Director of Operations of the Digital CMC Consortium, about the launch and what comes next.


    In this episode, Luke covers:


    (00:26) The launch: why biotechs, sponsors, CDMOs and consultancies have come together to solve the problems that can only be solved together.


    (01:18) Why sponsor to CDMO technology transfer is the first use case, and what a frictionless transfer would look like: as easy as moving to a new phone, instead of typing in every contact by hand.


    (02:55) How the consortium will turn standards into day-to-day practice: starting from the real workflow between sponsor and CDMO, building in pieces and iterating with members, and working with existing standards rather than replacing them.


    (04:27) What the consortium wants from the CPHI community: the varied perspectives of sponsors, CDMOs and equipment makers across the whole CMC value chain.


    Watch the full episode to hear how the Digital CMC Consortium plans to make tech transfer easier, so teams can focus on the real science.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Luke Guerrero

    LinkedIn: https://www.linkedin.com/in/lukeguerrero/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/ruby-collier/


    Timestamps:

    00:00 Introduction

    00:22 The launch of the Digital CMC Consortium

    01:06 Why tech transfer is the first use case

    02:46 Turning shared standards into everyday practice

    04:18 What the consortium wants from the CPHI community

    05:05 Closing thoughts


    #Newsbeat #ARTOTalent #CPHI #CPHIMilan #CMC #TechTransfer #DigitalTransformation #CDMO #Pharma

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    5 mins
  • CPHI Milan 2026 Newsbeat: Quotient Sciences Takes AI Into A Clinical Trial - Andy Lewis
    Nov 3 2026

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Quotient Sciences has announced interim results from its AI-driven clinical trial. After three years developing AI for formulation development, with 30 to 50% time savings, Quotient took the approach into the clinic to see if it could also learn how a formulation's composition relates to its performance in people.


    On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Andy Lewis, Chief Scientific Officer of Quotient Sciences, about the results and what they could mean for drug development.


    In this episode, Andy covers:


    (00:25) The interim results: the AI appears to have learned the link between composition and in vivo performance after testing just three prototypes, which could reduce the clinical testing a product needs.


    (01:25) How the algorithm learned: active learning with Bayesian optimisation, starting untrained, trained first on in vitro data and then on the emerging clinical data, with a safety committee reviewing every formulation it requested. When the team changed the target to rule out luck, it hit that one too.


    (03:27) What it could mean for modified release products: fewer formulation screens, faster clinical development, and an in silico model of the drug product, like a digital twin, that could support scale-up and post-approval changes such as a change of site.


    (05:05) What drug developers at CPHI Milan are most excited about: a first look at the pharmacokinetic data, and how the tool's visualisations map onto quality by design.


    Watch the full episode to hear how Quotient Sciences is using AI to save time at every step of drug product development.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Andy Lewis

    LinkedIn: https://www.linkedin.com/in/andylewis1/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/ruby-collier/


    Timestamps:

    00:00 Introduction

    00:16 Quotient's interim clinical trial results

    01:25 How the algorithm learned from each dosing period

    03:27 What it could mean for modified release development

    05:05 What drug developers at CPHI are excited about

    06:08 Closing thoughts


    #Newsbeat #ARTOTalent #CPHI #CPHIMilan #AI #MachineLearning #FormulationDevelopment #DrugDevelopment #ClinicalTrials

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    7 mins